CSPC Pharmaceutical Group and Daehwa Pharmaceutical both invested in a round that will be used to take Haihe's anti-tumour therapies further down the clinical path.
China-based cancer therapy developer Haihe Biopharma raised $146.6m yesterday in a funding round featuring drug producers CSPC Pharmaceutical Group and Daehwa Pharmaceutical.
Huagai Capital, Yingke PE, Hillhouse Capital, Atlas Capital, BioTrack Capital, Elite Capital and Chinese Academy of Sciences Venture Capital Management Co, which invests on behalf of the eponymous research organisation, also participated in the round.
Formed through the March 2018 merger of Haihe Pharmaceutical and RMX Biopharma, Haihe Biopharma is developing anti-tumour drugs and has a pipeline of…
